Details

Autor(en) / Beteiligte

• Chimenti, Maria Sole
• Fonti, Giulia Lavinia
• Conigliaro, Paola
• Sunzini, Flavia
• Scrivo, Rossana
• Navarini, Luca
• Triggianese, Paola
• Peluso, Giusy
• Scolieri, Palma
• Caccavale, Rosalba
• Picchianti Diamanti, Andrea
• De Martino, Erica
• Salemi, Simonetta
• Birra, Domenico
• Altobelli, Alessio
• Paroli, Marino
• Bruzzese, Vincenzo
• Laganà, Bruno
• Gremese, Elisa
• Conti, Fabrizio
• Afeltra, Antonella
• Perricone, Roberto

Titel

One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study

Ist Teil von

• Expert opinion on biological therapy, 2020-07, Vol.20 (7), p.813-821

Ort / Verlag

England: Taylor & Francis

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Taylor & Francis Journals Auto-Holdings Collection

Beschreibungen/Notizen

• Secukinumab (SEC) is effective for ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in randomized trials, but real-life data are lacking. Real-life, prospective observational study on 169 consecutive outpatients at baseline (T0) and at 6 (T6) and 12 months (T12) after starting SEC (39 AS, 23%; 130 PsA, 77%). Significant improvement was seen at T6 and T12 for all clinical variables, including TJC, SJC, ESR, CRP, DAPSA, ASDAS-CRP, and BASDAI, as well as in patient-reported outcomes like VAS-pain. By multivariable regression analysis, in AS patients high BASDAI at T0 correlated with diagnostic delay (R 2  = 0.4; p = 0.009) and peripheral joint involvement (R 2  = 0.4; p = 0.04). During follow-up, reduction of BASDAI positively correlated with high ESR (R 2  = 0.65; p = 0.04). ASDAS-CRP at T0 positively correlated with high ESR (R 2  = 0.34; p = 0.004). Reduction of ASDAS-CRP from T0 to T6 correlated with current smoking status (R 2  = 0.42; p = 0.003). In PsA patients, reduction of DAPSA score from T0 to T12 is negatively correlated with the presence of metabolic syndrome (R 2  = 0.41; p = 0.0025). SEC was well tolerated; 10 patients discontinued treatment for non-severe adverse events. Secukinumab is effective and safe in patients with AS and PsA in a real-life setting.